About us
Nacamed AS is an innovative pharmaceutical company focused on developing new drugs to address unmet medical needs. At the core of our technology lies a proprietary process for producing commercial-scale, tailor-made porous silicon-based nanoparticles designed for drug delivery and controlled hydrogen delivery.
Nacamed is a spin-off company of Dynatec AS. During the last decade the two companies have investigated in the production of Silicon particles, and have acquired unique competency.
Nacamed integrates this technical knowledge with pharmaceutical industry expertise to pioneer a new generation of clinical treatment methods.
Nacamed - Research and Development
Nacamed has own laboratories with relevant laboratory equipment including several HPLC systems. The Company also have extensive collaborations with both academic institutions and pharmaceutical companies in Norway and abroad.
IP Strategy
Nacamed has an active IP strategy and has filed several patent applications. Some of these patent families have been published.
WO2022223822 (Nacamed) Silicon particles for drug delivery. International patent application. Published 27102022.
WO2022223821 (Nacamed) Silicon particles for hydrogen release. International patent application. Published 27102022.
Publications
Nacamed has also an active publication strategy. One of Nacameds key employees (Hennie Marie Johnsen) performed her dissertation for Ph.D in 2025 in collaboration with Institute of Pharmacy, University of Oslo. Several of Nacameds publications are available in this site and in the open scientific publication databases.